primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma
European Journal of Cancer · 2026-09 · 245 · 116951
DOI: 10.1016/j.ejca.2026.116951 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-09. Verfasst von Alexander Cj van Akkooi und 37 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Faculty of Medicine and Health, University of Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Al…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carbamates, Melanoma. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut de recherche Pierre Fabre, Les Laboratories Pierre Fabre.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia, Faculty of Medicine and Health, University of Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: alexander.vanakk…
- EORTC Headquarters, Brussels, Belgium.
- Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Fakultni Nemocnice Kralovske Vinohrady, Prague, Czech Republic.
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
Förderung
- Institut de recherche Pierre Fabre
- Les Laboratories Pierre Fabre
Zitieren
APA
van Akkooi, A. C., Kicinski, M., Govaerts, A. S., Hauschild, A., Rutkowski, P., Arenberger, P., Ascierto, P. A., Tomczak, P., Quereux, G., De Galitiis, F., Dutriaux, C., Gebhardt, C., Kapiteijn, E., Machet, L., Berciano, M. G., Del Vecchio, M., Jalving, M., Jouary, T., Krajsova, I., …, & Mandala, M. (2026). primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma. European Journal of Cancer, 245, 116951. https://doi.org/10.1016/j.ejca.2026.116951
Vancouver
van Akkooi AC, Kicinski M, Govaerts AS, Hauschild A, Rutkowski P, Arenberger P, et al. primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma. European Journal of Cancer. 2026;245:116951. doi:10.1016/j.ejca.2026.116951
BibTeX
@article{vanAkkooi2026,
author = {van Akkooi, Alexander Cj and Kicinski, Michal and Govaerts, Anne-Sophie and Hauschild, Axel and Rutkowski, Piotr and Arenberger, Petr and Ascierto, Paolo A and Tomczak, Piotr and Quereux, Gaëlle and De Galitiis, Federica and Dutriaux, Caroline and Gebhardt, Christoffer and Kapiteijn, Ellen and Machet, Laurent and Berciano, Miguel Ga and Del Vecchio, Michele and Jalving, Mathilde and Jouary, Thomas and Krajsova, Ivana and Matkovic, Suzana and Merelli, Barbara and Mortier, Laurent and Pagès-Laurent, Pages-LaurentCecile and Palmieri, Giuseppe and Pracht, Marc and Vantuchova, Yvetta and Massi, Daniela and Elaut, Nathalie and de Schaetzen, Gaetan and Nuyens, Sarah and Jha, Nitish and Klauck, Isabelle and Sansas, Benoît and Vedovato, Jean Claude and Lorigan, Paul C and Long, Georgina V and Eggermont, Alexander Mm and Mandala, Mario},
title = {primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma},
journal = {European Journal of Cancer},
year = {2026},
volume = {245},
pages = {116951},
doi = {10.1016/j.ejca.2026.116951}
}
EUVIMED